Immunoblotting using multiple antigens is essential to demonstrate the true risk of Helicobacter pylori infection for gastric cancer

Alimentary Pharmacology and Therapeutics

Volumn 28, Issue 7, 2008, Pages 903-910

  Mitchell, H ^b   English, D R ^c   Elliott, F ^d,e   Gengos, M ^b   Barrett, J H ^d,e   Giles, G G ^c   Forman, D ^a,d,e  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PEPSINOGEN I;

ACCURACY; ADULT; AGED; ARTICLE; ATROPHIC GASTRITIS; CANCER RISK; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; STOMACH CANCER;

ADULT; AGED; ANTIGENS, BACTERIAL; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; IMMUNOBLOTTING; LOGISTIC MODELS; MALE; MIDDLE AGED; PEPSINOGEN A; PROSPECTIVE STUDIES; RISK ASSESSMENT; STOMACH NEOPLASMS;

EID: 50849111059     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03792.x     Document Type: Article

References (25)

1. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001 49: 347 53.
2. Sugiyama A, Maruta F, Ikeno T, et al. Helicobacter pylori infection enhances N-methyl-N-nitrosourea-induced stomach carcinogenesis in the Mongolian gerbil. Cancer Res 1998 58: 2067 9.
3. Pritchard DM, Przemeck SM. Review article: how useful are the rodent animal models of gastric adenocarcinoma? Aliment Pharmacol Ther 2004 19: 841 59.
4. Mizoshita T, Tsukamoto T, Takenaka Y, et al. Gastric and intestinal phenotypes and histogenesis of advanced glandular stomach cancers in carcinogen-treated, Helicobacter pylori-infected Mongolian gerbils. Cancer Sci 2006 97: 38 44.
5. Forman D. Helicobacter pylori: the gastric cancer problem. Gut 1998 1: S33 4.
6. Matysiak-Budnik T, Megraud F. Helicobacter pylori infection and gastric cancer. Eur J Cancer 2006 42: 708 16.
7. Peek RM Jr., Crabtree JE. Helicobacter infection and gastric neoplasia. J Pathol 2006 208: 233 48.
8. Correa P. The biological model of gastric carcinogenesis. IARC Sci Publ 2004 157: 301 10.
9. You WC, Brown LM, Zhang L, et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst 2006 98: 974 83.
10. Wong BC, Lam SK, Wong WM, et al., China Gastric Cancer Study Group. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004 291: 187 94.
11. Mera R, Fontham ET, Bravo LE, et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut 2005 54: 1536 40.
12. Chen LT, Lin JT, Tai JJ, et al. Long-term results of anti-Helicobacter pylori therapy in early stage gastric high grade transformed MALT lymphoma. J Natl Cancer Inst 2005 97: 1345 53.
13. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 2002 75: 347 54.
14. Munoz N, Bosch FX, de Sanjose S, et al., International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. New Engl J Med 2003 348: 518 27.
15. Ekstrom AM, Held M, Hansson LE, Engstrand L, Nyren O. Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection. Gastroenterology 2001 121: 784 91.
16. Brenner H, Arndt V, Stegmaier C, Ziegler H, Rothenbacher D. Is Helicobacter pylori infection a necessary condition for non-cardia gastric cancer? Am J Epidemiol 2004 159: 252 8.
17. Siman JH, Engstrand L, Berglund G, Forsgren A, Floren C-H. Helicobacter pylori and CagA seropositivity and its association with gastric and oesophageal carcinoma. Scand J Gastroenterol 2007 42: 933 40.
18. Sasazuki S, Inoue M, Iwasaki M, et al., Japan Public Health Center Study Group. Effect of Helicobacter pylori infection combined with CagA and pepsinogen status on gastric cancer development among Japanese men and women: a nested case-control study. Cancer Epidemiol Biomarkers Prev 2006 15: 1341 7.
19. Varis K, Sipponnen P, Laxen F, et al. Implications of serum pepsinogen in early endoscopic diagnosis of gastric cancer and dysplasia. Scand J Gastroenterol 2000 35: 950 6.
20. Rothman KJ, Greenland S. Modern Epidemiology, 2nd edn. Philadelphia, PA: Lippincott-Raven, 1998.
21. Xia HH, Kalantar JS, Wyatt JM, et al. High sensitivity and specificity of a laboratory-based serological test, pylori DTect ELISA, for detection of Helicobacter pylori infection. Diagn Microbiol Infect Dis 2000 36: 69 74.
22. Xia HH, Wong BC, Wong WM, et al. Optimal serological tests for the detection of Helicobacter pylori infection in the Chinese population. Aliment Pharmacol Ther 2002 16: 521 6.
23. Monteiro L, de Mascarel A, Sarrasqueta AM, et al. Diagnosis of Helicobacter pylori infection: noninvasive methods compared to invasive methods and evaluation of two new tests. Am J Gastroenterol 2001 96: 353 8.
24. Simán JH, Engstrand L, Berglund G, Florén CH, Forsgren A. Evaluation of western blot CagA seropositivity in Helicobacter pylori-seropositive and -seronegative subjects. Clin Diagn Lab Immunol 2005 12: 304 9.
25. Ye W, Held M, Enroth H, Kraaz W, Engstrand L, Nyren O. Histology and culture results among subjects with antibodies to CagA but no evidence of Helicobacter pylori infection with IgG ELISA. Scand J Gastroenterol 2005 40: 312 8.